AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)
Retrieved on:
Wednesday, January 19, 2022
Medicine, Euronext Paris, Survival, Patient, Research, Scientific Committee on Antarctic Research, B cell, Apoptosis, KOL, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PKI, AMF, Population, Safety, Diagnosis, Science, Lists of diseases, Degenerative disease, Disease, Smouldering, AB, Tyrosine kinase inhibitor, Tissue, Marketing, Itch, Emmanuel Berl, Company, Mast cell activation syndrome, Depression, PLOS One, Veterinary medicine, MCAS, Food, Inflammation, FDA, Prevalence, Cell, Euronext, ANSM, Glass, Molders, Pottery, Plastics and Allied Workers International Union, Lancet, Pharmaceutical industry, Vaccine, Mastocytosis
AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome.
Key Points:
- AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome.
- MCAS is a disease caused by inappropriate activation of mast cells, which can lead to mast cell mediator release symptoms with a severity ranging from mild to life-threatening.
- Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.
- AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.